https://www.reuters.com/business/...vid-vaccine-via-covax-2021-07-02/ "Taiwan's vaccine orders include 4.76 million doses from COVAX, though so far it has only received slightly more than 600,000 from the scheme, all AstraZeneca PLC (AZN.L) shots. Novavax, in an emailed statement, said it already had an agreement to supply its vaccine to the COVAX facility.Taiwan Health Minister Chen Shih-chung told reporters on Friday that apart from COVAX they were planning to talk about getting a "related quantity" direct from the company. ..."
May 27 2021 Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
…Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved / authorized in Q4 2021. Manufacturing will begin in the coming weeks to enable rapid access to the vaccine should it be approved.
. . Darüber hinaus plant Spahn dem Bericht zufolge mit 31,8 Millionen Impfstoffdosen des mRNA-Impfstoffs von Moderna und 18,3 Millionen Dosen des Vektor-Impfstoffs von Johnson & Johnson. Weitere 70 Millionen Dosen verteilen sich auf die Impfstoffe der Hersteller Sanofi (42 Millionen), Novavax (16,3 Millionen) und Valneva (elf Millionen).
NEW COVID Vaccine that Uses OLD TECHNOLOGY - Novavax
Waiting for a vaccine that uses tried and true technology? This vaccine is for you! Learn about this COVID-19 vaccine that will likely be approved in the US in a few months.
Novavax, Inc. (Symbol: NVAX) saw options trading volume of 21,174 contracts, representing approximately 2.1 million underlying shares or approximately 43.9% of NVAX's average daily trading volume over the past month, of 4.8 million shares. Especially high volume was seen for the $220 strike call option expiring July 02, 2021, with 1,338 contracts trading so far today, representing approximately 133,800 underlying shares of NVAX. https://www.nasdaq.com/articles/...ivity%3A-rlgy-nvax-mara-2021-07-02
FDA expects to grant EUA to Novavax COVID-19 vaccine
…The Food and Drug Administration (FDA) on Sunday said it expected to issue emergency use authorization to the Novavax COVID-19 vaccine, which is believed to be effective against coronavirus variants, including the Delta variant.
…(The EUA approval of Novavax is still pending with UK, India and America before they could complete their application here in the Philippines but we are expecting that they will soon send vaccines in the country.)
…So far, the Philippine FDA granted EUA to vaccine manufacturers Pfizer, AstraZeneca, Sinovac (CoronaVac vaccine), Gamaleya Institute (Sputnik V), Johnson & Johnson (Janssen), Bharat Biotech (Covaxin), and Moderna.
zugleich, wie einfach und schnell der Kurs hier desaströs ins Taumeln gerät...Also wieder warten auf Erholung und maximalen Anstieg...es nervt! Wird Zeit für die EUA/FDA Zulassung, whatever...damit diese Spielereien ein Ende haben!
Ja eigentlich scheint es alles klar, also gilt: Nicht bange machen lassen von den bigPlayern die den Kurs auf Ihr Wunschziel für einen guten Einstieg drücken wollen
Nichts für ein schwaches Herz... "Much of the volatility in NVAX stock is because the company is late to the Covid-19 vaccine party. Novavax has a sizable market opportunity supplying its vaccine to developing nations, and its vaccine could also be used to provide needed booster shots to people as antibodies against Covid-19 wane. However, the company has missed the opportunity to sell its vaccine to wealthy countries such as the U.S., Canada, Germany and Australia. Novavax’s Covid-19 vaccine follows three other Covid-19 shots that have already been approved for emergency use by the FDA..." https://www.nasdaq.com/articles/...-for-the-faint-of-heart-2021-07-05
"...Although the shot is likely to hit the market only around Q4, almost ten months behind market leaders, considering that Emergency Use Authorizations are likely to be filed in the U.S., U.K., and Europe by the end of Q3, the emergence of concerning new coronavirus variants and a relatively slow pace of vaccination outside the U.S. likely mean that demand for Novavax’s shot will remain strong. With questions regarding the efficacy and potential demand largely out of the way, the focus will turn to the ability of Novavax to produce and supply its vaccine at scale. The 34-year-old clinical-stage biotech has not produced a commercial product to date. While Novavax has its own production facilities in the Czech Republic and Sweden, it will largely count on partnerships with contract manufacturing organizations around the world to produce a bulk of its vaccines and the antigens and adjuvants that go into them. Novavax expects its total vaccine capacity to stand at about 100 million doses per month by the end of Q3 2021, scaling this up to approximately 150 million doses per month by the end of Q4. Of this, about one billion annualized doses will be manufactured by India’s Serum Institute,..."
https://www.fool.com/investing/2021/07/09/...tock-dropped-this-week/? "...This lack of information about the efficacy of Novavax's vaccine against the delta variant seems to be troubling investors to some extent. On the other hand, continued worries about COVID-19 fueled by the rise of new variants could translate to a greater market opportunity for the company if its vaccine proves to be highly effective at protecting against the variants...."
war nicht der Grund für den Kurssturz. An diesem Tag sind viele bzw. fast alle volatilen Biostocks gefallen. Hier machen die Daytrader wieder Kasse. Nur meine Meinung.
Banani
: notes from the RA Capital Covid discussion
…NVAX Prevent 19: very high efficacy.
In line with what we knew from previous studies. Safety profile good too. Looking like they should have some EUAs in the next couple of months.
Likely to start in UK, Canada, EU, Korea; FDA may be on tail end of Q3.
Manufacturing on track for 100M end of Q3; 150M end of Q4.
Where does NVAX fit in with all the others approved. Global need; 200 countries still with very few vaccines at all. Developing world, boosters. Existing contracts.
Shrinking market in developing world for the first set of vaccines.
Very good data coming (Oxford trial) to compare vaccines as boosters. Expect some results in July.
Really good head to head with Oxford study; immune response and tolerability. So far, it seems to favor protein vaccines like NVAX because of their tolerability.
…NVAX Prevent 19: very high efficacy.
In line with what we knew from previous studies. Safety profile good too. Looking like they should have some EUAs in the next couple of months.
Likely to start in UK, Canada, EU, Korea; FDA may be on tail end of Q3.
Manufacturing on track for 100M end of Q3; 150M end of Q4.
Where does NVAX fit in with all the others approved. Global need; 200 countries still with very few vaccines at all. Developing world, boosters. Existing contracts.
Shrinking market in developing world for the first set of vaccines.
Very good data coming (Oxford trial) to compare vaccines as boosters. Expect some results in July.
Really good head to head with Oxford study; immune response and tolerability. So far, it seems to favor protein vaccines like NVAX because of their tolerability.
…MRNA flu vaccine on a yearly basis will need to be monitored for myocarditis since this will have a higher dose.
In a world where there is a much safer protein vaccine, why would you want to use an mRNA vaccine? Perhaps if it has superior efficacy, but otherwise not.
Thread abonnieren
